A Phase I Trial of the PI3K Inhibitor Buparlisib Combined With Capecitabine in Patients With Metastatic Breast Cancer
Autumn J. McRee(University of North Carolina at Chapel Hill), Elizabeth Claire Dees(University of North Carolina at Chapel Hill), Karen E. Weck, Zachary A. Kornblum(University of North Carolina at Chapel Hill), Katherine E. Reeder‐Hayes(University of North Carolina at Chapel Hill), Lisa A. Carey(University of North Carolina at Chapel Hill), Charles M. Perou(University of North Carolina at Chapel Hill), William C. Zamboni(AstraZeneca (United Kingdom)), R F Phipps(University of North Carolina at Chapel Hill), Zhiyuan Hu(University of North Carolina at Chapel Hill), P. Kelly Marcom(Duke University), Dominic T. Moore(University of North Carolina at Chapel Hill), Carey K. Anders(Duke University)
Cited by 30
Related Papers
The Somatic Genomic Landscape of Glioblastoma
|Cell|2013|5.2k
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma
|Clinical Cancer Research|2004|2.7k
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
|Breast Cancer Research|2010|2.1k